David Kirn sold $754k of FDMT
See Remarks at 4D Molecular Therapeutics, Inc.. 58,333 shares at an average of $12.92, traded Oct 5, 2026, filed Oct 7, 2026.
Score components
- +15RoleOfficer
- +22Trade size$754k at market
- 0Share of holdings soldSold 7.6% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-417068, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | SOpen-market sale Common Stock10b5-1 | -58,061 | $12.92 | $750k | 709,425 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stock10b5-1 | -272 | $13.61 | $3,702 | 709,153 | 5 d ago |
Related signals
Other insiders at 4D Molecular Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | 4D Molecular Therapeutics, Inc. | Scott Bizily Chief Legal Officer | $22k 1,635 shares | -16% | |
| 25Weak | 4D Molecular Therapeutics, Inc. | David Kirn See Remarks | $811k 58,333 shares | -7% | |
| 0Weak | 4D Molecular Therapeutics, Inc. | Scott Bizily Chief Legal Officer | $8,176 584 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.